Canada proposes new submission type for emergency-use drugs
This article was originally published in SRA
The Canadian Department of Health has proposed amendments to its regulations on emergency-use drugs, such as anthrax and pandemic influenza vaccines, to create a new type of drug submission that would subject these products to comprehensive pre-market review and enhanced post-market surveillance1,2.
You may also be interested in...
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.